Demetrios N Karatzas1, Konstantinos Xanthopoulos1, Panorea Kotantaki1, Athanasios Pseftogas1, Konstantinos Teliousis2, Eudoxia G Hatzivassiliou3, Dimitris L Kontoyiannis4, Theofilos Poutahidis2, George Mosialos5. 1. School of Biology, Aristotle University of Thessaloniki, 54124, Thessaloniki, Macedonia, Greece. 2. Laboratory of Pathology, Faculty of Veterinary Medicine, Aristotle University of Thessaloniki, 54124, Thessaloniki, Macedonia, Greece. 3. Laboratory of Biological Chemistry, Medical School, Aristotle University of Thessaloniki, 54124, Thessaloniki, Macedonia, Greece. 4. Biomedical Sciences Research Centre 'Alexander Fleming', 16672, Vari, Greece. 5. School of Biology, Aristotle University of Thessaloniki, 54124, Thessaloniki, Macedonia, Greece. gmosialo@bio.auth.gr.
Abstract
PURPOSE: CYLD is a tumor suppressor that has been linked to the development of various human malignancies, including colon cancer. The tumor-suppressing function of CYLD is associated with its deubiquitinating activity, which maps to the carboxyl-terminal region of the protein. In the present study we evaluated the role of intestinal epithelial CYLD in colitis-associated cancer using a conditional mouse CYLD inactivation model. METHODS: In order to evaluate the role of CYLD in intestinal epithelial carcinogenesis, mice (IEC-Cyld (Δ9) mice) that carry a mutation that eliminates the deubiquitinating domain of CYLD in intestinal epithelial cells (IEC) were generated by crossing Villin-Cre transgenic mice to previously generated mice carrying a loxP-flanked Cyld exon 9 (Cyld (flx9) mice). RESULTS: We found that IEC-Cyld (Δ9) mice did not present spontaneous intestinal abnormalities up to one year of age. However, upon challenge with a combination of genotoxic (AOM) and pro-inflammatory (DSS) agents we found that the number of adenomas in the IEC-Cyld (Δ9) mice was dramatically increased compared to the control mice. Inactivation of CYLD in intestinal epithelial cells did not affect the classical nuclear factor-kappaB (NF-κB) and c-Jun kinase (JNK) activation pathways under physiological conditions, suggesting that these pathways do not predispose CYLD-deficient intestinal epithelia to colorectal cancer development before the onset of genotoxic and/or pro-inflammatory stress. CONCLUSIONS: Our findings underscore a critical tumor-suppressing role for functional intestinal epithelial CYLD in colitis-associated carcinogenesis. CYLD expression and its associated pathways in intestinal tumors may be exploited for future prognostic and therapeutic purposes.
PURPOSE:CYLD is a tumor suppressor that has been linked to the development of various humanmalignancies, including colon cancer. The tumor-suppressing function of CYLD is associated with its deubiquitinating activity, which maps to the carboxyl-terminal region of the protein. In the present study we evaluated the role of intestinal epithelial CYLD in colitis-associated cancer using a conditional mouseCYLD inactivation model. METHODS: In order to evaluate the role of CYLD in intestinal epithelial carcinogenesis, mice (IEC-Cyld (Δ9) mice) that carry a mutation that eliminates the deubiquitinating domain of CYLD in intestinal epithelial cells (IEC) were generated by crossing Villin-Cre transgenic mice to previously generated mice carrying a loxP-flanked Cyld exon 9 (Cyld (flx9) mice). RESULTS: We found that IEC-Cyld (Δ9) mice did not present spontaneous intestinal abnormalities up to one year of age. However, upon challenge with a combination of genotoxic (AOM) and pro-inflammatory (DSS) agents we found that the number of adenomas in the IEC-Cyld (Δ9) mice was dramatically increased compared to the control mice. Inactivation of CYLD in intestinal epithelial cells did not affect the classical nuclear factor-kappaB (NF-κB) and c-Jun kinase (JNK) activation pathways under physiological conditions, suggesting that these pathways do not predispose CYLD-deficient intestinal epithelia to colorectal cancer development before the onset of genotoxic and/or pro-inflammatory stress. CONCLUSIONS: Our findings underscore a critical tumor-suppressing role for functional intestinal epithelial CYLD in colitis-associated carcinogenesis. CYLD expression and its associated pathways in intestinal tumors may be exploited for future prognostic and therapeutic purposes.
Authors: G R Bignell; W Warren; S Seal; M Takahashi; E Rapley; R Barfoot; H Green; C Brown; P J Biggs; S R Lakhani; C Jones; J Hansen; E Blair; B Hofmann; R Siebert; G Turner; D G Evans; C Schrander-Stumpel; F A Beemer; A van Den Ouweland; D Halley; B Delpech; M G Cleveland; I Leigh; J Leisti; S Rasmussen Journal: Nat Genet Date: 2000-06 Impact factor: 38.330
Authors: K Vazquez-Santillan; J Melendez-Zajgla; L Jimenez-Hernandez; G Martínez-Ruiz; V Maldonado Journal: Cell Oncol (Dordr) Date: 2015-08-29 Impact factor: 6.730
Authors: Isabelle Cleynen; Emilie Vazeille; Marta Artieda; Hein W Verspaget; Magdalena Szczypiorska; Marie-Agnès Bringer; Peter L Lakatos; Frank Seibold; Kirstie Parnell; Rinse K Weersma; Jestinah M Mahachie John; Rebecca Morgan-Walsh; Dominiek Staelens; Ingrid Arijs; Gert De Hertogh; Stefan Müller; Atilla Tordai; Daniel W Hommes; Tariq Ahmad; Cisca Wijmenga; Sylvia Pender; Paul Rutgeerts; Kristel Van Steen; Daniel Lottaz; Severine Vermeire; Arlette Darfeuille-Michaud Journal: Gut Date: 2013-10-03 Impact factor: 23.059
Authors: Jonathan J Keats; Rafael Fonseca; Marta Chesi; Roelandt Schop; Angela Baker; Wee-Joo Chng; Scott Van Wier; Rodger Tiedemann; Chang-Xin Shi; Michael Sebag; Esteban Braggio; Travis Henry; Yuan-Xiao Zhu; Homer Fogle; Tammy Price-Troska; Gregory Ahmann; Catherine Mancini; Leslie A Brents; Shaji Kumar; Philip Greipp; Angela Dispenzieri; Barb Bryant; George Mulligan; Laurakay Bruhn; Michael Barrett; Riccardo Valdez; Jeff Trent; A Keith Stewart; John Carpten; P Leif Bergsagel Journal: Cancer Cell Date: 2007-08 Impact factor: 31.743
Authors: Christina M Annunziata; R Eric Davis; Yulia Demchenko; William Bellamy; Ana Gabrea; Fenghuang Zhan; Georg Lenz; Ichiro Hanamura; George Wright; Wenming Xiao; Sandeep Dave; Elaine M Hurt; Bruce Tan; Hong Zhao; Owen Stephens; Madhumita Santra; David R Williams; Lenny Dang; Bart Barlogie; John D Shaughnessy; W Michael Kuehl; Louis M Staudt Journal: Cancer Cell Date: 2007-08 Impact factor: 31.743
Authors: Christine M Costello; Nancy Mah; Robert Häsler; Philip Rosenstiel; Georg H Waetzig; Andreas Hahn; Tim Lu; Yesim Gurbuz; Susanna Nikolaus; Mario Albrecht; Jochen Hampe; Ralph Lucius; Günther Klöppel; Holger Eickhoff; Hans Lehrach; Thomas Lengauer; Stefan Schreiber Journal: PLoS Med Date: 2005-08-23 Impact factor: 11.069